Pharmacokinetics

• 1. Introduction

  ›

  Pharmacokinetics asks a question that sounds almost philosophical: what does the body do to a drug? Not what the drug does to the body, but the reverse. The field, abbreviated as PK, traces the life of a chemical from the moment it enters the body to the moment it disappears entirely. Its name comes from the Ancient Greek pharmakon, meaning drug, and kinetikos, meaning moving or putting in motion. Together those roots describe a discipline built on watching things travel. Pharmacokinetics does not cover only medicines. It covers any chemical xenobiotic a person or animal might absorb, from pesticides to food additives to cosmetics, following each substance through the same rigorous lens. At the heart of PK is a mathematical relationship: drug plasma concentration plotted against time. That single curve encodes almost everything a clinician or researcher needs to know. What the curve looks like, how it rises and falls, and why it behaves differently in different bodies are the questions this documentary will explore.

• 2. ADME: A Drug's Journey

  ›

  Every substance that enters the body moves through a sequence of phases captured by the acronym ADME, or LADME when liberation is counted as its own step. Liberation is where active pharmaceutical ingredients separate from whatever formulation carries them. Absorption follows, pulling the drug from its entry point into the bloodstream. Distribution then spreads the substance through fluids and tissues across the body. Metabolism, also called biotransformation or inactivation, breaks the drug down chemically, often through enzymes such as cytochrome P450 or glucuronosyltransferase. Excretion removes what remains. In rare cases, some drugs do not leave at all; they accumulate irreversibly in body tissue. Different authors slice these phases differently. Some textbooks merge liberation and absorption because many drugs arrive already in active form, leaving no meaningful liberation step. Others bundle distribution, metabolism, and excretion together as a single disposition phase. A further group appends the drug's toxicological dimension, yielding frameworks labeled ADME-Tox or ADMET. Metabolism and excretion are often grouped under the single heading of elimination. To understand any of these phases in depth requires knowledge of excipient properties, the biology of membranes, and the enzyme reactions that can either speed or block a drug's breakdown.

• 3. Measuring What Matters

  ›

  A worked example in the pharmacokinetics literature illustrates just how precisely these phases can be quantified. A dose of 500 mmol produces a peak plasma concentration of 60.9 mmol/L, reached at 3.9 hours after administration. The elimination half-life, meaning the time for that concentration to fall to half its original value, is 12 hours. Clearance, the volume of plasma cleared of drug per unit of time, comes to 0.38 liters per hour. Bioavailability in this example sits at 0.8, or 80%, meaning one fifth of whatever is administered never reaches systemic circulation. Steady state is reached once the body's intake and elimination are in dynamic equilibrium. In practice, that equilibrium arrives after 3 to 5 times the drug's half-life under regular dosing. In steady-state linear pharmacokinetics, the area under the curve for a single dosing interval equals the total area under the curve after a single infinite dose, a relationship that anchors much of the arithmetic used in clinical and industrial settings. The area under the concentration-time curve, or AUC, is the workhorse metric for total drug exposure, and the trapezoidal rule is the most common numerical method for estimating it. Because the trapezoidal rule depends on the spacing of time points, tighter blood-sampling schedules produce more accurate area estimates.

• 4. Models and Their Limits

  ›

  Noncompartmental analysis estimates pharmacokinetic parameters directly from a concentration-time table without assuming any particular biological structure. It is versatile and generally accurate enough for bioequivalence studies. Compartmental analysis takes a different approach, treating the organism as a system of differential equations where the body is divided into interacting compartments. Single-compartment models treat the entire body as one homogenous space, assuming that blood plasma concentration tells you everything about drug concentration everywhere else. This works when concentrations elsewhere can be approximated by fixed, known ratios relative to plasma. First-order elimination, where the rate of removal is directly proportional to the drug's current concentration, is the most common model within the single-compartment framework; mathematicians call this linear pharmacokinetics. Two-compartment models recognize that not all tissues share the same blood supply. Organs with rich circulation form the central compartment; slower-perfused organs constitute the peripheral compartment. The brain occupies a special position: its blood-brain barrier can be crossed more or less easily depending on a drug's lipophilicity and its ability to evade active efflux. In both central and peripheral compartments, elimination most often happens in the central compartment because the liver and kidneys are well-supplied with blood, though some drugs are eliminated in the peripheral compartment or in both simultaneously. The most complex pharmacokinetic models are called PBPK models. They incorporate detailed physiological information to make development and validation more tractable. Despite their sophistication, all models make simplifying assumptions, and none truly replicate reality. The volume of distribution, a central parameter in these models, is explicitly described as a relative concept rather than a true physical measurement.

• 5. When Linearity Breaks Down

  ›

  Non-linear pharmacokinetics emerges whenever the body's handling of a drug stops scaling proportionally with dose. Enzymatic saturation is one cause: if the dose exceeds the threshold above which metabolizing enzymes are overwhelmed, plasma concentrations rise faster than the dose, and elimination becomes unpredictable. Some drugs interfere with their own metabolism through induction or inhibition of enzymes in positive or negative feedback loops. Fluvoxamine, fluoxetine, and phenytoin are named in the pharmacokinetic literature as examples of pharmaceuticals that do this. As doses of those drugs climb, the concentration of unmetabolized drug rises and the elimination half-life lengthens, making dose adjustment necessary. Intravenous drugs also exhibit a biphasic pattern: an initial alpha phase, where rapid distribution from circulation into tissues causes a steep drop in plasma concentration, followed by a slower beta phase dominated by metabolism and excretion. Additional phases beyond alpha and beta, labeled gamma, delta, and so on, sometimes appear. The kidneys can create their own non-linearity by running active elimination mechanisms that are independent of plasma concentration entirely. Because non-linearity can enter through absorption, distribution, metabolism, or elimination, identifying exactly where it originates requires tracking the full ADME sequence.

• 6. Bioavailability and Bioequivalence

  ›

  Intravenous administration sets the gold standard for bioavailability at a value of 1, or 100%, because nothing is lost between the injection site and systemic circulation. Every other delivery route is measured against that benchmark, either as absolute bioavailability compared to IV, or as relative bioavailability compared to a standard within a given study. A simple formula captures the clinical reality: the effective dose equals bioavailability multiplied by the administered dose. If bioavailability is 0.8 and the administered dose is 100 milligrams, only 80 milligrams carries genuine pharmaceutical potential. Factors that determine a drug's bioavailability include its pharmaceutical form, chemical form, route of administration, stability, and how it is metabolized. When two drugs share identical bioavailability, they are called bioequivalents. Bioequivalence is currently the primary criterion used in many countries for authorizing generic drugs, making it one of the most practically consequential concepts the field has produced.

• 7. From Lab to Clinic

  ›

  Population pharmacokinetics, or popPK, examines why drug concentrations vary across individuals receiving the same dose. Body weight, kidney and liver function, and concurrent therapies can all alter the relationship between dose and concentration. Patients with kidney failure, for instance, typically reach higher steady-state concentrations of renally eliminated drugs than patients with normal kidney function on the same regimen. An important practical advantage of population pharmacokinetic modelling is its ability to extract useful estimates from sparse data, sometimes as little as a single plasma measurement per patient. Clinical pharmacokinetics applies that population knowledge directly to individual therapeutic decisions. The relaunch of ciclosporin as an immunosuppressant illustrates what clinical PK can achieve. After ciclosporin's therapeutic value was established, its use was almost abandoned because of nephrotoxicity in a number of patients. Pharmacokinetic monitoring, tracking each patient's individual plasma concentrations and adjusting dose accordingly, made it possible to use the drug safely, and the technique has since enabled a large number of organ transplants. Clinical monitoring most commonly targets plasma concentration because that data is the easiest to obtain and most reliable. Drugs with a narrow gap between therapeutic and toxic concentrations, high inherent toxicity, or a high risk to life when mismanaged, are the candidates most often placed under pharmacokinetic monitoring; the list includes antiepileptic drugs such as phenytoin and carbamazepine, immunosuppressors such as ciclosporin and tacrolimus, antibiotics such as vancomycin and gentamicin, and cytostatics such as methotrexate.

• 8. Beyond Medicine

  ›

  Ecotoxicology extends pharmacokinetic thinking beyond human medicine to the environment itself. Substances harmful to the biosphere, including pesticides and microplastics, enter the bodies of living organisms and follow the same ADME logic that governs pharmaceutical drugs. Government and international agencies, including the EPA and WHO, conduct health-effects research and safety trials on these compounds. Lethal dose, duration of retention in the body, and the nature of biological interactions are the central questions ecotoxicology investigates. Mass spectrometry, specifically liquid chromatography combined with triple quadrupole mass spectrometry, has become the dominant analytical tool for measuring drug concentrations in complex biological matrices such as plasma and urine. Tandem mass spectrometry adds a further layer of specificity. A promising development in this space is Secondary electrospray ionization mass spectrometry, or SESI-MS, which can monitor drugs without requiring animal sacrifice, an advantage researchers regard as an alternative to conventional animal experimentation.